Lunaphore Appoints Dr. Carlo Bifulco to Scientific Advisory Board
Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, announces the appointment of Dr. Carlo Bifulco, an expert in Translational Molecular Pathology and Pathology Informatics, to its Scientific Advisory Board (SAB) to provide strategic advisory support to the company’s scientific activities and product portfolio development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210617005459/en/
Dr. Carlo Bifulco (Photo: Business Wire)
Dr. Bifulco is a Surgical Pathologist with additional fellowship subspecialty training, expertise, and board certification in Molecular Genetic Pathology and Hematopathology. Dr. Bifulco serves on the Global Colon Cancer Immunoscore Task Force led by the Society for Immunotherapy of Cancer (SITC) and is co-Chair of the SITC Pathology Task convened to establish multiplexed immunohistochemistry/immunofluorescence (mIHC/IF) standards.
His current translational research is focused on supporting the characterization of the tumor immune microenvironment through immunohistochemical and image analysis techniques, and on the integration of genomics in immuno-oncology.
Dr. Bifulco’s role in the SAB will be to bring strategic insights that will enable Lunaphore to become leaders in the field of high-dimensional analysis of histopathological samples and to support the company in the establishment of scientific partnerships with key stakeholders in coming years.
“We are very excited to have Dr. Bifulco join us as we seek to bring our microfluidic-based platforms to the next-level.” noted Dr. Dupouy, CTO at Lunaphore. “Dr. Bifulco is an innovative Pathologist, whose insights will be invaluable for Lunaphore to harness the potential of multiplexed immunofluorescence in the field of translational research as well as to provide us with a better understanding of US-focused clinical practices, even more so in this era of cancer immunotherapy”.
“I am very excited by Lunaphore’s microfluidic technological advances, aiming to improve speed, reliability, reproducibility and accuracy of tissue-based biomarker testing”, said Dr. Bifulco. “Physician decision-making in personalized medicine needs robust biomarkers, and solutions such as Lunaphore’s Fast-Fluidic Exchange (FFeX) may become instrumental to improving patient outcomes”.
Dr. Bifulco currently serves as the Director of Molecular Pathology and Pathology Informatics at Providence, and as the Director of Translational Molecular Pathology and Molecular Genomics at the Earle A. Chiles Research Institute in Portland, Oregon, a division of the Providence Cancer Institute. He oversees the Province System Molecular Genomics Laboratory, one of the largest clinical genomics labs in the Pacific Northwest, which provides state-of-the-art genomic sequencing to cancer patients across the seven-state system. Prior to joining Providence, Dr. Bifulco served on the Pathology faculty at the National Cancer Center in Milan, at the University of Florida and at Yale University, and completed fellowships in Hematopathology at Yale and in Oncologic Surgical Pathology and Molecular Genetic Pathology at Memorial Sloan Kettering Cancer Center.
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company transforming the field of tissue analytics in cancer research through the development of innovative staining and imaging technology platforms. The award-winning technology at its core is called FFeX (Fast Fluidic Exchange). Using high-precision microfluidics, complex assays can be automated, extracting comprehensive data much faster than current techniques. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue analytics and has been recognized as one of the most innovative companies internationally. For further information on Lunaphore and its products, please visit www.lunaphore.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005459/en/
Contact information
Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com
Théophile Mounier
Lunaphore Corporate Finance
Email: theophile.mounier@lunaphore.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 07:00:00 EET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 03:15:00 EET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 18:59:00 EET | Press release
Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through battle-tested AI Agents at enterprise scale. The new funds will accelerate the adoption of the Torq AI SOC Platform, the only end-to-end solution built on
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom